CompletedPHASE1, PHASE2NCT05475379
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
Studying Typhoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Principal Investigator
- Farhana Khanam, MPhil, PhD, LMFT, LPCCInternational Centre for Diarrhoeal Disease Research, Bangladesh
- Intervention
- Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)(biological)
- Enrollment
- 630 target
- Eligibility
- 60 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05475379 on ClinicalTrials.govOther trials for Typhoid
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950Induction of Gut Permeability by an Oral VaccineUSDA, Western Human Nutrition Research Center
- ACTIVE NOT RECRUITINGPHASE3NCT03299426Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiUniversity of Maryland, Baltimore
- ACTIVE NOT RECRUITINGPHASE4NCT03970304CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsUniversity of Maryland, Baltimore